June Corry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
June Corry has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
11 shared publicationsLester J. Peters
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
7 shared publications- Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3 shared publications Richard Fisher
University of Melbourne, Melbourne, Australia
3 shared publicationsSandro Porceddu
3 shared publications- Alexander Dobrovic
Olivia Newton-John Cancer and Wellness Centre, Melbourne, Australia
2 shared publications
Latest Publications
- Open Access
Current Radiotherapy Considerations for Nasopharyngeal Carcinoma
Radiotherapy is the primary treatment modality for nasopharyngeal carcinoma (NPC). Successful curative treatment requires optimal radiotherapy planning and precise beam delivery that maximizes locoregional control while minimizing treatment-related side effects. In this article, we highlight considerations in target delineation, radiation dose, and the adoption of technological advances with the aim of optimizing the benefits of radiotherapy in NPC patients.
Open AccessCurrent Radiotherapy Considerations for Nasopharyngeal Carcinoma
Radiotherapy is the primary treatment modality for nasopharyngeal carcinoma (NPC). Successful curative treatment requires optimal radiotherapy planning and precise beam delivery that maximizes locoregional control while minimizing treatment-related side effects. In this article, we highlight considerations in target delineation, radiation dose, and the adoption of technological advances with the aim of optimizing the benefits of radiotherapy in NPC patients.
- Open Access
- 18 July 2016
- Published by Springer Nature in Clinical Epigenetics
- Vol. 8 (1) , 1-12
Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas
DNA methylation profiling of heterogeneous head and neck squamous cell carcinoma (HNSCC) cohorts has been reported to predict patient outcome. We investigated if a prognostic DNA methylation profile could be found in tumour tissue from a single uniform subsite, the oral tongue. The methylation status of 109 comprehensively annotated oral tongue squamous cell carcinoma (OTSCC) formalin-fixed paraffin-embedded (FFPE) samples from a single institution were examined with the Illumina HumanMethylation450K (HM450K) array. Data pre-processing, quality control and analysis were performed using R packages. Probes mapping to SNPs, sex chromosomes and unreliable probes were accounted for prior to downstream analyses. The relationship between methylation and patient survival was examined using both agnostic approaches and feature selection. The cohort was enlarged by incorporation of 331 The Cancer Genome Atlas (TCGA) HNSCC samples, which included 91 TCGA OTSCC samples with HM450K and survival data available. Given the use of FFPE-derived DNA, we defined different cohorts for separate analyses. Overall, similar results were found between cohorts. With an unsupervised approach, no distinct hypermethylated group of samples was identified and nor was a prognostic methylation profile identified. The use of multiple downstream feature selection approaches, including a linear models for microarray data (LIMMA), centroid feature selection (CFS), and recursive feature elimination (RFE) support vector machines, similarly failed to identify a significant methylation signature informative for patient prognosis or any clinicopathological data available. Furthermore, we were unable to confirm the prognostic methylation profiles or specific prognostic loci reported within the literature for HNSCC. With genome-scale assessment of DNA methylation using HM450K in one of the largest OTSCC cohorts to date, we were unable to identify a hypermethylated group of tumours or a prognostic methylation signature. This suggests that either DNA methylation in isolation is not likely to be of prognostic value or larger cohorts are required to identify such a biomarker for OTSCC.
- 18 July 2016
- Published by Springer Nature in Clinical Epigenetics
- Vol. 8 (1) , 1-12
Open AccessGenome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas
DNA methylation profiling of heterogeneous head and neck squamous cell carcinoma (HNSCC) cohorts has been reported to predict patient outcome. We investigated if a prognostic DNA methylation profile could be found in tumour tissue from a single uniform subsite, the oral tongue. The methylation status of 109 comprehensively annotated oral tongue squamous cell carcinoma (OTSCC) formalin-fixed paraffin-embedded (FFPE) samples from a single institution were examined with the Illumina HumanMethylation450K (HM450K) array. Data pre-processing, quality control and analysis were performed using R packages. Probes mapping to SNPs, sex chromosomes and unreliable probes were accounted for prior to downstream analyses. The relationship between methylation and patient survival was examined using both agnostic approaches and feature selection. The cohort was enlarged by incorporation of 331 The Cancer Genome Atlas (TCGA) HNSCC samples, which included 91 TCGA OTSCC samples with HM450K and survival data available. Given the use of FFPE-derived DNA, we defined different cohorts for separate analyses. Overall, similar results were found between cohorts. With an unsupervised approach, no distinct hypermethylated group of samples was identified and nor was a prognostic methylation profile identified. The use of multiple downstream feature selection approaches, including a linear models for microarray data (LIMMA), centroid feature selection (CFS), and recursive feature elimination (RFE) support vector machines, similarly failed to identify a significant methylation signature informative for patient prognosis or any clinicopathological data available. Furthermore, we were unable to confirm the prognostic methylation profiles or specific prognostic loci reported within the literature for HNSCC. With genome-scale assessment of DNA methylation using HM450K in one of the largest OTSCC cohorts to date, we were unable to identify a hypermethylated group of tumours or a prognostic methylation signature. This suggests that either DNA methylation in isolation is not likely to be of prognostic value or larger cohorts are required to identify such a biomarker for OTSCC.
- 10 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (2) , 138-140
Impact of Center Size and Experience on Outcomes in Head and Neck Cancer
- 10 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (2) , 138-140
Impact of Center Size and Experience on Outcomes in Head and Neck Cancer
- Open Access
- 9 December 2014
- Published by Springer Nature in Clinical Epigenetics
- Vol. 6 (1) , 22
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome
DNA hypermethylation is reported as a frequent event and prognostic marker in head and neck squamous cell carcinomas (HNSCC). Methylation has been commonly assessed with non-quantitative methodologies, such as methylation-specific PCR (MSP). We investigated previously reported hypermethylated genes with quantitative methodology in oral tongue squamous cell carcinomas (OTSCC). The methylation status of 12 genes in 115 OTSCC samples was assessed by one or more of three quantitative analyses: methylation sensitive high resolution melting (MS-HRM), sensitive-melting analysis after real time-methylation specific PCR (SMART-MSP), and bisulfite pyrosequencing. In contrast to much of the literature, either no or infrequent locus-specific methylation was identified by MS-HRM for DAPK1, RASSF1A, MGMT, MLH1, APC, CDH1, CDH13, BRCA1, ERCC1, and ATM. The most frequently methylated loci were RUNX3 (18/108 methylated) and ABO (22/107 methylated). Interrogation of the Cancer Genome Atlas (TCGA) HNSCC cohort confirmed the frequency of significant methylation for the loci investigated. Heterogeneous methylation of RUNX3 (18/108) and ABO (22/107) detected by MS-HRM, conferred significantly worse survival (P = 0.01, and P = 0.03). However, following quantification of methylation levels using pyrosequencing, only four tumors had significant quantities (>15%) of RUNX3 methylation which correlated with a worse patient outcome (P <0.001), while the prognostic significance of ABO hypermethylation was lost. RUNX3 methylation was not prognostic for the TCGA cohort (P = 0.76). We demonstrated the critical need for quantification of methylation levels and its impact on correlative analyses. In OTSCC, we found little evidence of significant or frequent hypermethylation of many loci reported to be commonly methylated. It is likely that previous reports have overestimated the frequency of significant methylation events as a consequence of the use of non-quantitative methodology.
- 9 December 2014
- Published by Springer Nature in Clinical Epigenetics
- Vol. 6 (1) , 22
Open AccessQuantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome
DNA hypermethylation is reported as a frequent event and prognostic marker in head and neck squamous cell carcinomas (HNSCC). Methylation has been commonly assessed with non-quantitative methodologies, such as methylation-specific PCR (MSP). We investigated previously reported hypermethylated genes with quantitative methodology in oral tongue squamous cell carcinomas (OTSCC). The methylation status of 12 genes in 115 OTSCC samples was assessed by one or more of three quantitative analyses: methylation sensitive high resolution melting (MS-HRM), sensitive-melting analysis after real time-methylation specific PCR (SMART-MSP), and bisulfite pyrosequencing. In contrast to much of the literature, either no or infrequent locus-specific methylation was identified by MS-HRM for DAPK1, RASSF1A, MGMT, MLH1, APC, CDH1, CDH13, BRCA1, ERCC1, and ATM. The most frequently methylated loci were RUNX3 (18/108 methylated) and ABO (22/107 methylated). Interrogation of the Cancer Genome Atlas (TCGA) HNSCC cohort confirmed the frequency of significant methylation for the loci investigated. Heterogeneous methylation of RUNX3 (18/108) and ABO (22/107) detected by MS-HRM, conferred significantly worse survival (P = 0.01, and P = 0.03). However, following quantification of methylation levels using pyrosequencing, only four tumors had significant quantities (>15%) of RUNX3 methylation which correlated with a worse patient outcome (P <0.001), while the prognostic significance of ABO hypermethylation was lost. RUNX3 methylation was not prognostic for the TCGA cohort (P = 0.76). We demonstrated the critical need for quantification of methylation levels and its impact on correlative analyses. In OTSCC, we found little evidence of significant or frequent hypermethylation of many loci reported to be commonly methylated. It is likely that previous reports have overestimated the frequency of significant methylation events as a consequence of the use of non-quantitative methodology.
- 1 June 2013
- Published by Wiley in Head & Neck
- Vol. 36 (3) , 317-322
Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation
Background: The primary purpose of this study was to review the efficacy of unilateral treatment of lateralized tonsil primaries, in particular whether laterality of the primary is a more powerful determinant of contralateral neck failure than advanced ipsilateral nodal classification.Methods: A retrospective study of all patients with tonsillar cancer treated with curative intent between January 1990 and December 2002 was performed.Results: There were 167 patients, 76% men, median age 58 years, 86% current or ex‐smokers. The majority of patients (58%) had stage IV disease. Five‐year local, nodal, locoregional, and distant failure rates were 14%, 4%, 18%, and 8%, respectively. Of the 58 patients treated unilaterally, 33% had N2a, N2b, or N3 nodal disease. There were no contralateral nodal failures in the unilaterally treated group.Conclusion: These results support the potential use of unilateral radiation therapy (RT) for lateralized tonsil primaries even with advanced ipsilateral nodal disease. © 2013 Wiley Periodicals, Inc. Head Neck 36: 317–322, 2014
- 1 June 2013
- Published by Wiley in Head & Neck
- Vol. 36 (3) , 317-322
Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation
Background: The primary purpose of this study was to review the efficacy of unilateral treatment of lateralized tonsil primaries, in particular whether laterality of the primary is a more powerful determinant of contralateral neck failure than advanced ipsilateral nodal classification.Methods: A retrospective study of all patients with tonsillar cancer treated with curative intent between January 1990 and December 2002 was performed.Results: There were 167 patients, 76% men, median age 58 years, 86% current or ex‐smokers. The majority of patients (58%) had stage IV disease. Five‐year local, nodal, locoregional, and distant failure rates were 14%, 4%, 18%, and 8%, respectively. Of the 58 patients treated unilaterally, 33% had N2a, N2b, or N3 nodal disease. There were no contralateral nodal failures in the unilaterally treated group.Conclusion: These results support the potential use of unilateral radiation therapy (RT) for lateralized tonsil primaries even with advanced ipsilateral nodal disease. © 2013 Wiley Periodicals, Inc. Head Neck 36: 317–322, 2014
- 1 February 2011
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (2) , 113-114
Induction chemotherapy in head and neck cancer: closer to an answer?
- 1 February 2011
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (2) , 113-114
Induction chemotherapy in head and neck cancer: closer to an answer?
- 1 March 2010
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (3) , 287-291
Optimising the therapeutic ratio in head and neck cancer
- 1 March 2010
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (3) , 287-291
Optimising the therapeutic ratio in head and neck cancer
- 1 October 2009
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 53 (5) , 431-432
Feeding tubes and dysphagia: cause or effect in head and neck cancer patients.
- 1 October 2009
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 53 (5) , 431-432
Feeding tubes and dysphagia: cause or effect in head and neck cancer patients.
- 18 March 2009
- Published by Wiley in Head & Neck
- Vol. 31 (7) , 867-876
Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation
Background: Percutaneous endoscopic gastrostomy (PEG) tubes have largely replaced nasogastric tubes (NGTs) for nutritional support of patients with head and neck cancer undergoing curative (chemo) radiotherapy without any good scientific basis.Methods: A prospective study was conducted to compare PEG tubes and NGTs in terms of nutritional outcomes, complications, patient satisfaction, and cost.Results: There were 32 PEG and 73 NGT patients. PEG patients sustained significantly less weight loss at 6 weeks post‐treatment (median 0.8 kg gain vs 3.7 kg loss, p < .001), but had a high insertion site infection rate (41%), longer median duration of use (146 vs 57 days, p < .001), and more grade 3 dysphagia in disease‐free survivors at 6 months (25% vs 8%, p = .07). Patient self‐assessed general physical condition and overall quality of life scores were similar in both groups. Overall costs were significantly higher for PEG patients.Conclusion: PEG tube use should be selective, not routine, in this patient population. © 2009 Wiley Periodicals, Inc. Head Neck, 2009
- 18 March 2009
- Published by Wiley in Head & Neck
- Vol. 31 (7) , 867-876
Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation
Background: Percutaneous endoscopic gastrostomy (PEG) tubes have largely replaced nasogastric tubes (NGTs) for nutritional support of patients with head and neck cancer undergoing curative (chemo) radiotherapy without any good scientific basis.Methods: A prospective study was conducted to compare PEG tubes and NGTs in terms of nutritional outcomes, complications, patient satisfaction, and cost.Results: There were 32 PEG and 73 NGT patients. PEG patients sustained significantly less weight loss at 6 weeks post‐treatment (median 0.8 kg gain vs 3.7 kg loss, p < .001), but had a high insertion site infection rate (41%), longer median duration of use (146 vs 57 days, p < .001), and more grade 3 dysphagia in disease‐free survivors at 6 months (25% vs 8%, p = .07). Patient self‐assessed general physical condition and overall quality of life scores were similar in both groups. Overall costs were significantly higher for PEG patients.Conclusion: PEG tube use should be selective, not routine, in this patient population. © 2009 Wiley Periodicals, Inc. Head Neck, 2009